Abstract PURPOSE: To examine the utility of polycythemia rubra vera-1 (PRV-1)–specific reverse transcriptase polymerase chain reaction (RT-PCR) to discriminate essential thrombocythemia (ET) and ...
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...
The FDA accepted Besremi's application for essential thrombocythemia, supported by SURPASS-ET and EXCEED-ET trial results, with a review target date of August 30, 2026. Essential thrombocythemia is a ...
"These patients [with extreme thrombocytosis] had improved overall survival and lower bleeding risk compared to those with normal or low platelet counts at the time of diagnosis." — Marko Lucijanic, ...
John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...
Preliminary findings from 51 evaluable ET patients showed treatment with INCA033989 monotherapy demonstrated rapid and durable normalization of platelet counts. The Food and Drug Administration (FDA) ...
Change in platelet counts was a common phenomenon after major joint surgery, and elevated PLTC occurred in about half of the patients who were admitted to the rehabilitation centre. Thrombocytosis was ...
The risk of venous and arterial thrombosis in polycythemia vera patients with secondary malignancies. Temporal trends in myeloproliferative neoplasms–related mortality in the United States over the ...
John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback